This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Aran Labrijn, PhD
Principal Scientist, Antibody Research and Technology at Genmab

Profile

Dr. Aran F. Labrijn has been working in the field of recombinant antibodies for more than 20 years. He holds a PhD in molecular immunology from the University of Amsterdam (2004). In 2002, he joined Genmab where he is currently a principal scientist in the department of antibody research and technology with a focus on understanding antibody biology and Fc-engineering. These studies have led to the development of therapeutic antibody formats, including Genmab’s bispecific antibody technology platform (DuoBody®).

Agenda Sessions

  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #5: BISPECIFIC ANTIBODIES: NEW APPROACHES AND CASE STUDIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #5 in the Watch On-Demand Sessions Tab prior to this session

    15:45
  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #2: THE “NUTS AND BOLTS” OF ANTIBODIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #2 in the Watch On-Demand Sessions Tab prior to this session

    14:30
  • SESSION CHAIR: Mark Your Calendar for Wednesday, August 26, 15:45-16:30 for the Live Speaker Q&A/Panel Discussion with the Speakers in this Session - Check the "Watch Live" Session Tab for Details. We Recommend That You Watch These On-Demand Presentations Prior to the Live Q&A/Panel

    On Demand
  • The Essential Guide to Bispecific Antibodies

    On Demand